Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 24 Show results per page	View Search Criteria \| Help With Results


1.		First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				D8480C00013 Eudract Number 2005-003440-66, NCT00384176


2.		Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				D8480C00051 EUDRACT No 2006-001194-14, HORIZON II, NCT00399035

Last Modified: 11/2/2007 First Published: 10/5/2007


3.		Phase III Randomized Study of Platinum-Based Chemotherapy (PBC) Comprising Carboplatin and Paclitaxel Versus Concurrent Cediranib and PBC Versus Concurrent and Maintenance Cediranib and PBC in Women With Platinum-Sensitive Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				MRC-NCRI-ICON6 MRC-NCRI-ICON6, EUDRACT-2007-001346-41, EU-20765, ZENECA-MRC-NCRI-ICON6, NCT00544973


4.		Phase III: Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				D8480C00055 NCT00777153

Last Modified: 11/25/2008 First Published: 11/19/2008


5.		Phase III randomized Study of Paclitaxel and Carboplatin With Versus Without Cediranib In Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				CAN-NCIC-BR29 BR29, NCT00795340


6.		A Phase I/II Study of AZD2171 in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				D8480C00039 NCT00494221

Last Modified: 5/21/2008 First Published: 4/17/2008


7.		Phase I/II Study of Cediranib, Temozolomide, and Radiotherapy in Patients With Newly Diagnosed Glioblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				MGH-07-344 07-344, 8030, NCT00662506

Last Modified: 5/13/2008 First Published: 3/24/2006


8.		Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				NCI				UCCRC-14203B NCI-7103, 7103, NCT00309946

Last Modified: 12/4/2008 First Published: 5/11/2006


9.		Phase II Study AZD2171 in Patients With Neurofibromatosis Type 1 and Extensive Plexiform and/or Paraspinal Neurofibromas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI				MAYO-MC047F 7133, NCI-7133, NCT00326872

Last Modified: 5/28/2008 First Published: 1/19/2007


10.		Phase II Study of AZD2171 in Patients With Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Approved-not yet active				18 and over				NCI				MGH-05-311 7147, NCT00427973

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute